Within a clinical phase I/II combined chemoimmunotherapy trial of patients with metastatic colorectal cancer we assessed frequencies of FOXP3-expressing CD4+CD25high Treg cells in peripheral blood before initiation of therapy in comparison to healthy controls (Fig. 1A). This evidence concerns the gene FOXP3 and metastatic colorectal cancer.